• 1
    Tesse A, Martinez MC, Meziani F et al. Origin and biological significance of shed-membrane microparticles. Endocr Metab Immune Disord Drug Targets 2006; 6: 287294.
  • 2
    Morel O, Toti F, Hugel B et al. Procoagulant microparticles: Disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 25942604.
  • 3
    Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48: 180186.
  • 4
    Morel O, Toti F, Bakouboula B, Grunebaum L, Freyssinet JM. Procoagulant microparticles: ‘criminal partners’ in atherothrombosis and deleterious cellular exchanges. Pathophysiol Haemost Thromb 2006; 35: 1522.
  • 5
    Preston RA, Jy W, Jimenez JJ et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211217.
  • 6
    Goichot B, Grunebaum L, Desprez D et al. Circulating procoagulant microparticles in obesity. Diabetes Metab 2006; 32: 8285.
  • 7
    Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 24422447.
  • 8
    Chironi G, Simon A, Hugel B et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26: 27752780.
  • 9
    Morel O, Hugel B, Jesel L et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 11181126.
  • 10
    Ojo AO, Hanson JA, Meier-Kriesche H et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589597.
  • 11
    Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 17251730.
  • 12
    Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 16621668.
  • 13
    Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(Suppl 15): S186.
  • 14
    Faure V, Dou L, Sabatier F et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006; 4: 566573.
  • 15
    Meehan SM, Limsrichamrern S, Manaligod JR et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum Pathol 2003; 34: 533540.
  • 16
    Amabile N, Guerin AP, Leroyer A et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16: 33813388.
  • 17
    Daniel L, Fakhouri F, Joly D et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006; 69: 14161423.
  • 18
    Al-Massarani G, Vacher-Coponat H, Paul P et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008; 8: 23602367.
  • 19
    Jy W, Horstman LL, Jimenez JJ et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 18421851.
  • 20
    Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763773.
  • 21
    Takahashi K, Ikeoka K, Nojima M, Shima H, Ohyanagi M. Effect of renal transplantation on the cardiac function of patients with hemodialysis. J Cardiol 2007; 49: 2329.
  • 22
    Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914919.
  • 23
    Horl WH. Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13(Suppl 1): S6271.
  • 24
    Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007; 66: 159165.
  • 25
    Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 2311123118.
  • 26
    Mause SF, Von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: A transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005; 25: 15121518.
  • 27
    Petersen E, Baird BC, Shihab F et al. The impact of recipient history of cardiovascular disease on kidney transplant outcome. Asaio J 2007; 53: 601608.
  • 28
    Mallat ZSG, Hugel B, Tanguy ML et al. Prognostic value of circulating shed membrane pro-coagulant microparticles in patients with severe acute coronary syndrome. A substudy from the registre of acute coronary events (GRACE). Circulation 2004; 110: 575 (abstract 2676).
  • 29
    Nampoory MR, Das KC, Johny KV et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003; 42: 797805.
  • 30
    Ballow A, Gader AM, Huraib S, Mitwalli A, Al-Suleimani F, Al-Wakeel J. Successful kidney transplantation does not reverse the coagulopathy in patients with chronic renal failure on either hemo or peritoneal dialysis. Saudi J Kidney Dis Transpl 2007; 18: 177185.
  • 31
    Pham PT, Pham PC, Danovitch GM. Cardiovascular disease posttransplant. Semin Nephrol 2007; 27: 430444.
  • 32
    Boots JM, Van Duijnhoven EM, Christiaans MH, Nieman FH, Van Suylen RJ, Van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14: 370383.
  • 33
    Yano Y, Shiba E, Kambayashi J et al. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb Res 1993; 71: 385396.
  • 34
    Garcia E, Stracher A, Jay D. Calcineurin dephosphorylates the C-terminal region of filamin in an important regulatory site: A possible mechanism for filamin mobilization and cell signaling. Arch Biochem Biophys 2006; 446: 140150.
  • 35
    Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem J 1991; 274(Pt 2): 611614.
  • 36
    Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993; 25: 14611469.
  • 37
    Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307(Pt 1): 9398.